The inverse benefit law: How drug marketing undermines patient safety and public health

American Journal of Public Health

Volumn 101, Issue 3, 2011, Pages 399-404

  Brody, Howard ^a   Light, Donald W ^b  

^a Institute for the Medical Humanities   (United States)

^b University of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PRESCRIPTION DRUG;

ARTICLE; DRUG CONTROL; DRUG INDUSTRY; DRUG SURVEILLANCE PROGRAM; ETHICS; HEALTH CARE POLICY; HUMAN; MARKETING; ORGANIZATION AND MANAGEMENT; POSTMARKETING SURVEILLANCE; PUBLIC HEALTH; SAFETY;

ADVERSE DRUG REACTION REPORTING SYSTEMS; DRUG AND NARCOTIC CONTROL; DRUG INDUSTRY; HEALTH POLICY; HUMANS; MARKETING; PRESCRIPTION DRUGS; PRODUCT SURVEILLANCE, POSTMARKETING; PUBLIC HEALTH; SAFETY;

EID: 79951594704     PISSN: 00900036     EISSN: 15410048     Source Type: Journal    
DOI: 10.2105/AJPH.2010.199844     Document Type: Article

References (50)

1. Hart JT. The inverse care law. Lancet. 1971;1(7696):405-412.
2. Tudor Hart J. Commentary: three decades of the inverse care law. BMJ. 2000;320:18-19. (Pubitemid 30173006)
3. A look back at pharmaceuticals in 2006: aggressive advertising cannot hide the absence of therapeutic advances. Prescrire Int. 2007;16:80-86.
4. Olson MK. Are novel drugs more risky for patients than less novel drugs? J Health Econ. 2004;23:1135-1158. (Pubitemid 39535588)
5. Carpenter D, Zucker EJ, Avorn J. Drug-review deadlines and safety problems. N Engl J Med. 2008;358:1354-1361. (Pubitemid 351468412)
6. McCormack J, Greenhalgh T. Seeing what you want to see in randomized controlled trials: versions and perversions of UKPDS data. United Kingdom prospective diabetes study. BMJ. 2000;320 (7251):1720-1723. (Pubitemid 30410489)
7. Davidson MB, Schriger DL, Peters AL, Lorber B. Relationship between fasting plasma glucose and glycosylated hemoglobin: potential for false-positive diagnoses of type 2 diabetes using new diagnostic criteria. JAMA. 1999;281: 1203-1210. (Pubitemid 29163129)
8. Selvin E, Bolen S, Yeh HC, et al. Cardiovascular outcomes in trials of oral diabetes medications: a systematic review. Arch Intern Med. 2008;168:2070-2080.
9. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356:2457-2471. (Pubitemid 46919772)
10. Gale EA. Lessons from the glitazones: a story of drug development. Lancet. 2001;357:1870-1875. (Pubitemid 32539124)
11. Choudhry NK, Stelfox HT, Detsky AS. Relationships between authors of clinical practice guidelines and the pharmaceutical industry. JAMA. 2002;287: 612-617. (Pubitemid 34252013)
12. Abramson J, Wright JM. Are lipidlowering guidelines evidence-based? Lancet. 2007;369:168-169.
13. National Heart, Lung, and Blood Institute, National Cholesterol Education Program. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): Final Report (NIH publication 02-5215). September 2002. Available at: http://www. nhlbi.nih.gov/guidelines/cholesterol/ atp3full.pdf. Accessed May 3, 2008.
14. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110:227-239. (Pubitemid 38924592)
15. Kassirer JP. Why should we swallow what these studies say? Washington Post. August 1, 2004:B3.
16. Abramson J. Overdosed America: The Broken Promise of American Medicine. New York, NY: HarperCollins; 2004: 210-220.
17. Tyrer P, Kendall T. The spurious advance of antipsychotic drug therapy. Lancet. 2009;373:4-5.
18. Spielmans GI. The promotion of olanzapine in primary care: an examination of internal industry documents. Soc Sci Med. 2009;69:14-20.
19. Healy D. Shaping the intimate: influences on the experience of everyday nerves. Soc Stud Sci. 2004;34:219-245. (Pubitemid 38726847)
20. Light DW, ed. The Risks of Prescription Drugs. New York, NY: Columbia University Press; 2010.
21. Spiegel BM, Targownik L, Dulai GS, Gralnek IM. The cost-effectiveness of cyclooxygenase-2 selective inhibitors in the management of chronic arthritis. Ann Intern Med. 2003;138:795-806.
22. Wright JM. The double-edged sword of COX-2 selective NSAIDs. CMAJ. 2002; 167:1131-1137.
23. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA. 2001;286:954-959. (Pubitemid 33010342)
24. Dai C, Stafford RS, Alexander GC. National trends in cyclooxygenase-2 inhibitor use since market release: nonselective diffusion of a selectively cost-effective innovation. Arch Intern Med. 2005;165:171-177.
25. Groopman J. Super aspirin: new arthritis drug-Celebra. New Yorker. June 15, 1998:32.
26. Topol EJ. Failing the public health-rofecoxib, Merck, and the FDA [perspective]. N Engl J Med. 2004;351: 1707-1709. (Pubitemid 39383201)
27. Graham DJ, Campen D, Hui R, et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and nonselective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet. 2005;365:475-481. (Pubitemid 40215729)
28. Moynihan R, Heath I, Henry D. Selling sickness: the pharmaceutical industry and disease mongering. BMJ. 2002;324:886-891.
29. Moynihan R, Cassels A. Selling Sickness: How the World's Biggest Pharmaceutical Companies Are Turning Us All Into Patients. New York, NY: Nation Books; 2005.
30. Argyropoulos SV, Hood SD, Nutt DJ. Social phobia: illness or illusion? Acta Psychiatr Scand. 2001;103:241-243.
31. Starcevic V. Opportunistic "rediscovery" of mental disorders by the pharmaceutical industry. Psychother Psychosom. 2002;71:305-310. (Pubitemid 36151505)
32. Julius S, Nesbitt SD, Egan BM, et al. Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med. 2006;354:1685-1697.
33. Rosenstock J. Reflecting on type 2 diabetes prevention: more questions than answers! Diabetes Obes Metab. 2007; 9(suppl 1):3-11. (Pubitemid 47433963)
34. DREAM trial investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomized controlled trial. Lancet. 2006; 368(9541):1096-1105.
35. Napoli M. The marketing of osteoporosis. Am J Nurs. 2009;109(4):58-61.
36. Steinman MA, Harper GM, Chren MM, Landefeld CS, Bero LA. Characteristics and impact of drug detailing for gabapentin. PLoS Med. 2007;4(4):e134.
37. Wilson D. For $520 million, Astra- Zeneca settles case over marketing of a drug. The New York Times. April 27, 2010. Available at: http://www.nytimes.com/2010/04/28/business/28drug.html?emc=tnt&tntemail0=y. Accessed June 11, 2010.
38. Stafford RS. Regulating off-label drug use-rethinking the role of the FDA. N Engl J Med. 2008;358:1427-1429. (Pubitemid 351482734)
39. Østbye T, Yarnall KS, Krause KM, Pollak KI, Gradison M, Michener JL. Is there time for management of patients with chronic diseases in primary care? Ann Fam Med. 2005;3:209-214. (Pubitemid 40806713)
40. Avorn J. Powerful Medicines: The Benefits, Risks and Costs of Prescription Drugs. New York, NY: Knopf; 2004.
41. Selker HP, Wood AJJ. Industry influence on comparative effectiveness research funded through health care reform [perspective]. N Engl J Med. 2009;361: 2595-2597.
42. Frances A. A warning sign on the road to DSM-beware of its unintended consequences. Psychiatric Times. June 26, 2009:26(8). Available at: http://www.psychiatrictimes.com/display/article/10168/1425378. Accessed March 23, 2010.
43. Dresser R, Frader J. Off-label prescribing: a call for heightened professional and government oversight. J Law Med Ethics. 2009;37:476-486.
44. Campbell EG, Gruen RL, Mountford J, et al. A national survey of physician-industry relationships. N Engl J Med. 2007;356: 1742-1750. (Pubitemid 46658706)
45. National Physicians Alliance. The unbranded doctor campaign. Available at: http://npalliance.org/content/pages/the-unbranded-doctor-campaign. Accessed June 11, 2010.
46. DeAngelis CD, Fontanarosa PB. Impugning the integrity of medical science: the adverse effects of industry influence. JAMA. 2008;299:1833-1835. (Pubitemid 351549977)
47. Brody H. Hooked: Ethics, the Medical Profession, and the Pharmaceutical Industry. Lanham, MD: Rowman and Littlefield; 2007.
48. Brennan TA, Rothman DJ, Blank L, et al. Health industry practices that create conflicts of interest: a policy proposal for academic medical centers. JAMA. 2006; 295:429-433. (Pubitemid 43144979)
49. Rothman DJ, McDonald WJ, Berkowitz CD, et al. Professional medical associations and their relationships with industry. JAMA. 2009;301:1367-1372.
50. Baucus M, Grassley CE. Use of educational grants by pharmaceutical manufacturers. Washington, DC: US Senate Finance Committee; April 2007 (S. Prt 110-21). Available at: http://finance.senate.gov/library/prints. Accessed March 23, 2010.